Novartis’ pelacarsen trial fails to cut cardiovascular risk

The pivotal cardiovascular outcomes trial did not meet its primary endpoint

Tangram Therapeutics advances TGM-312 into MASH patient cohorts

The company expects to report interim data from MASH patients in 2027

Summit’s ivonescimab delivers overall survival win against pembrolizumab in Phase III lung cancer trial

Suven Life Sciences completes Phase 3 enrollment for Masupirdine in Alzheimer’s agitation

Suven expects the last patient last visit (LPLV) by the end of December 2026

AbbVie’s etentamig cuts risk of progression by 60% in Phase 3 multiple myeloma trial

Both were dual primary endpoints of the trial, and the differences were statistically significant, AbbVie said

Teva’s Celiac drug shows positive Phase 2a results preventing gluten-induced intestinal damage

The study met its primary endpoint

AstraZeneca and HUTCHMED report major first-line lung cancer win with Tagrisso-Orpathys

The findings from the SANOVO trial in China strengthen the case for Tagrisso as a backbone treatment for EGFR-mutated non-small cell lung cancer

GSK moves toward first Phase III trial of mRNA flu vaccine targeting both HA and NA

GSK plans to begin a Phase III efficacy trial in September 2026

Novartis’ Remibrutinib delivers positive Phase III results in relapsing multiple sclerosis

The results point to potential benefits beyond relapse control

Inceptua Group acquires SupplyRx to strengthen clinical trial pharmacy services

The acquisition is expected to strengthen Inceptua's Pharmacy Model capabilities in North America

Lilly’s Taltz-Zepbound combination delivers stronger one-year results in psoriatic disease & obesity trials

The results build on statistically superior outcomes reported at Week 36, when the combination outperformed Taltz alone on key disease and metabolic measures

HaemaLogiX treats first patient with KMCAR T-cell therapy in Phase I multiple myeloma trial

The Australian biotech player is evaluating the therapy in patients with relapsed or refractory kappa-restricted multiple myeloma

Zydus’ Saroglitazar Mg clears key hurdle in global MASH trial

EVIDENCES-X trial met its primary endpoint, with a 26.5% treatment difference in MASH resolution without worsening of fibrosis

Roche’s Vabysmo delivers sustained vision gains in two-year PCV data

The treatment also enabled longer dosing intervals for many patients

Tezspire delivers positive Phase III results in eosinophilic esophagitis

The trial’s two co-primary endpoints assessed histologic remission and the frequency and severity of dysphagia

AbbVie seeks EU nod for subcutaneous SKYRIZI induction in Crohn’s disease

The study’s co-primary endpoints were clinical remission, defined as a Crohn’s Disease Activity Index (CDAI) score below 150

Creative Medical completes Olastrocel trial enrollment as it sets sights on FDA Phase 3 path

Kynexis raises €40 million to push cognition drug toward late-stage trials

Kynexis has completed enrollment in the Phase 2 study and expects to report topline results by the end of 2026

Novo Nordisk begins late-stage trial to test lower-dose oral Wegovy for weight loss

The 60-week, randomised Phase III study will enrol 450 adults with a BMI of 30 or above, or 27 or above with at least one obesity-related health condition

AstraZeneca’s Enhertu delivers first-line win in HER2-mutant lung cancer trial

The trial will continue to assess secondary endpoints, including overall survival